Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort

OBJECTIVE: This phase I clinical study (NCT01415297) evaluated the safety, tolerability, maximum-tolerated dose (MTD), pharmacokinetics and pharmacodynamics of IT-139 (formerly NKP-1339) monotherapy in patients with advanced solid tumours. IT-139, sodium trans-(tetrachlorobis(1H-indazole)ruthenate(I...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:ESMO Open
Auteurs principaux: Burris, Howard A, Bakewell, Suzanne, Bendell, Johanna C, Infante, Jeffrey, Jones, Suzanne F, Spigel, David R, Weiss, Glen J, Ramanathan, Ramesh K, Ogden, Angela, Von Hoff, Daniel
Format: Artigo
Langue:Inglês
Publié: ESMO Open 2017
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5548977/
https://ncbi.nlm.nih.gov/pubmed/28848672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000154
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires